International Journal of Hematology

DOI: 10.1007/s12185-016-2008-0 Pages: 300-309

Histone deacetylase inhibitors in multiple myeloma: from bench to bedside

1. Harvard Medical School, Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute

Correspondence to:
Teru Hideshima
Email: teru_hideshima@dfci.harvard.edu

Close

Abstract

Histone deacetylases (HDACs) deacetylate the lysine residues of both histones and non-histone proteins. Histone acetylation results in a loose local chromatin structure that regulates gene-specific transcription. Non-histone proteins can also be acetylated, leading to dynamic changes in their activity and stability. For these reasons, HDAC inhibition has emerged as a potential approach for the treatment of MM. Specifically, combination treatment with HDAC inhibitors and proteasome inhibitors or immunomodulatory drugs shows remarkable anti-MM activity in both preclinical and clinical settings. However, the clinical studies using non-selective HDAC inhibitors also cause unfavorable side effects in patients, leading us to develop more isoform- and/or class–selective HDAC inhibitors to enhance tolerability without diminishing anti-MM activity, thereby improving patient outcome in MM.

This article is freely available, click here to access the full text/PDF

Share the Knowledge